Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 54.74

-2.1%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John McCarthy who wrote (14123)	11/15/2004 1:03:38 PM
From: Biomaven	Read Replies (1) of 52153

Thanks for posting that. Nice to see them quoting Harry. Even nicer if the trial works, of course. <g> pricing in the range of $5,000 per course of therapy Seems like they could charge more if it's truly effective. If it gets you out of the ICU a few days earlier, or means a better recovery, then $5k is cheap. TBI is incredibly expensive - I've not seen cost figures, but I'm guessing that for moderate injuries $100k has to be very much the bottom of the range. Stock has bounced back recently - up nearly 50% off its lows of about a month ago. No idea what that means, but my cynical side says a small Israeli company is likely to be leakier than a US company. (No position) Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next